HUTCHMED Ltd (HCM) Form 6-K — Jun 25, 2026
HUTCHMED announced positive pivotal Phase II results for fanregratinib in intrahepatic cholangiocarcinoma presented at the ESMO Gastrointestinal Cancers Congress. The study demonstrated a clinically meaningful objective response rate of 42.5% and a disease control rate of 83.9% in pretreated patients. Secondary endpoints showed rapid and durable responses, with a median time to response of 1.4 months and a median overall survival of 16.6 months. The safety profile was manageable, with only 2.2% of patients discontinuing treatment due to drug-related adverse events.
Key figures
- Orr
- 42.5%
- Disease Control Rate
- 83.9%
- Duration Of Response
- 6.9 months
- Discontinuation Rate
- 2.2%
- Grade3 Adverse Events
- 48.3%
- Median Time To Response
- 1.4 months
- Median Overall Survival
- 16.6 months
- Median Progression Free Survival
- 6.9 months
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.